ENTA’s preclinical NASH candidates are “10-500 times as potent as OCA,” according to the JPM webcast (21-minute mark). The guidance is to select a lead compound during 2015.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”